Sanofi SA (NAS:SNY)
$ 48.29 -0.1 (-0.21%) Market Cap: 121.07 Bil Enterprise Value: 139.04 Bil PE Ratio: 26.55 PB Ratio: 1.57 GF Score: 84/100

Sanofi SA to Discuss Collaboration With Translate Bio to Develop a Novel mRNA Vaccine Candidate Against COVID-19 Conference Call Transcript

Mar 27, 2020 / 02:30PM GMT
Release Date Price: $42.44 (-1.19%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi conference call on the expansion of their collaboration with Translate Bio to develop a COVID-19 vaccine.

I would now like to turn the call over to Felix Lauscher from Sanofi Investor Relations. Please go ahead, sir.

Felix Lauscher
Sanofi SA - Head of IR North America & Asia

Thank you. Good morning, and good afternoon to everyone on the call. We hope everyone is well. Thank you for joining us to review the details of this important new initiative against the coronavirus. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.

Moving to Slide 2. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document de Référence for a description of these risk factors.

With that, please

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot